SINGAPORE, 1 October 2021 – MiRXES Pte Ltd, a Singapore-headquartered biotechnology company focused on improving and saving lives with RNA-powered disease early detection tests, announced today the appointment of Mr. Cher Hwa TEO as Senior Vice President (SVP), Health Innovation Delivery and Chief of Staff. As the SVP of Health Innovation Delivery, Mr. Teo will help embed MiRXES into the Singapore healthcare ecosystem through downstream market access efforts by driving greater advocacy towards the adoption of MiRXES’s technology and products. Mr. Teo will be double hatting and in his role as Chief of Staff, he will assist MiRXES’s Co-founder and CEO, Dr. Lihan ZHOU in overseeing strategic initiatives from development to successful execution, as well as working closely with the functional heads in decision-making, program management, and initiative implementation. Based in Singapore, Mr. Teo will report to Dr. Zhou.
“We are pleased to welcome Cher Hwa into our MiRXES family where his knowledge and experience of Singapore and regional healthcare ecosystems can help MiRXES accelerate the delivery of early, actionable and personalized diagnoses across the care continuum to save and improve lives more effectively,” said Dr. Zhou. “Cher Hwa is an outstanding and trusted leader. I have confidence that in his capacity as Chief of Staff, he will be able to help guide MiRXES’s fast growing team forward by identifying and addressing knowledge and skills gaps, as well as seeking opportunities to optimize our current processes and organizational procedures for efficiency and productivity.”
Mr. Teo brings with him over 20 years of experience in grant funding, technology transfer, product development, and commercializing innovative technologies in telecommunications and biomedical devices. Currently he is on several biomedical grant review panels with SMART Innovation Centre, A*STAR, NMRC, SingHealth, CGH, and SUTD, to name a few. Mr. Teo was most recently with the National Health Innovation Centre Singapore (NHIC) as the Director of the NHIC and was also their founding member. In addition to providing guidance and support in funding, mentoring and assisting deal formation to the Singapore publicly funded healthcare institutions, he also led a team of innovators that promoted the collaboration of researchers, clinicians and industry to better position Singapore in tackling the anticipated healthcare challenges of tomorrow. In this role, Mr. Teo had secured over SGD20 million of funding for biomedical and health projects from the public healthcare institutions.
Prior to joining NHIC, Mr. Teo was the Vice President of the Communications & Healthcare Cluster at A*STAR’s A*ccelerate Technologies for seven years, where he oversaw technology transfer activities such as IP management, licensing, industry collaboration and translational funding projects in the MedTech and communications sectors.
Mr. Teo said, “I am honoured to have the opportunity to shape MiRXES’s future with like-minded individuals who are equally passionate about saving and improving lives as I am. I look forward to working closely with the talented teams at MiRXES to ensure we continue to deliver accurate preventive healthcare solutions for cancer, cardiovascular, metabolic and infectious diseases, and make them accessible to all.”
Mr. Teo also has extensive experience in product management, sales & marketing, systems engineering and business development for mission critical systems and communications products in the telecommunications industry when he was the Deputy Director (Comms Systems) of ST Electronics (Info-comm Systems) before moving into the healthcare sector.
Mr. Teo holds a Bachelor of Engineering (First Class Hons) in Electronic Engineering from the University of Sheffield and an MBA from the University of Manchester.
Founded in 2014 as a spin-off from Singapore’s Agency for Science, Technology, and Research (A*STAR) with strong support from the National University of Singapore (NUS), MiRXES is a leading developer of RNA-powered tests for disease early detection, with strong pipelines in multiple cancer types, as well as in cardiovascular, metabolic and infectious diseases. MiRXES is headquartered in Singapore, with operations in China, Japan and the United States, as well as commercial activities in over 45 countries globally. In 2019, MiRXES launched GASTROClear, the world’s first microRNA blood test for early detection of gastric cancer. The MiRXES’s multi-cancer early detection pipeline includes screening tests for lung, colorectal, liver, and breast cancer. In response to the COVID-19 pandemic in 2020, MiRXES worked closely with A*STAR, Diagnostics Development Hub (DxD) and Tan Tock Seng Hospital (TTSH) to mass produce Fortitude Kit, Singapore’s first authorized COVID-19 RT-PCR test. Since February 2020, more than 8 million Fortitude Kits have been deployed globally.
For more information, visit www.mirxes.com
Follow us on LinkedIn @ https://www.linkedin.com/company/mirxes/